explore -WSS

explore

author：entertainment 2025-10-01 11:09:25 Page View：62134

Astrazeneca office building -- health policy coverage from STAT — AstraZeneca is suing the Biden administration to stop a new Medicare drug price negotiation program. Adobe

WASHINGTON — AstraZeneca is the sixth drugmaker to pile on a legal challenge to the Biden administration’s drug pricing reform law.

The Medicare drug price negotiation program created in the Inflation Reduction Act is set to kick off in the next week, as officials will release the names of the first 10 medicines that will be selected for the program. Medicines are eligible for selection if they are one of the highest-spend drugs for Medicare, and they have no generic competition.

AstraZeneca makes drugs that could be selected for the list, and asked a Delaware district court judge to rule that Medicare acted illegally and that the law is unconstitutional.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Merck drug for rare lung condition set for approval in U.S.
Next article： After affirmative action ruling, medical educators look to 'holistic review'

explore

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

ALS patient reclaims some autonomy thanks to wearable 'robot'

AlexHogan/STATJohnGoodsonpracticedmedicineforalmost50yearsatMassachusettsGeneralHospitalinBoston.Asa

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

Curing rare childhood diseases will falter unless Congress steps up

AdobeWhenoursonPeterwasdiagnosedwithanultra-rareformofmusculardystrophyattheageof10,thefirstquestion

explore

comprehensive

explore

Curing rare childhood diseases will falter unless Congress steps up